TABLE 3.
Studies reporting on the association between anthropometric factors and breast cancer risk in US Hispanic women1
| Premenopausal |
Postmenopausal |
|||||||||
| First author, year (ref) | Age, y | Study design | Exposure | Contrast | Cases/controls, n | Risk estimate | 95% CI | Cases/controls, n | Risk estimate | 95% CI |
| Young-adult BMI | ||||||||||
| Wenten, 2002 (73) | 30–74 | PCC | BMI (kg/m2) age 18 y | ≥25 vs. <18.5 | 114/145 | 1.34 | 0.38, 4.70 | 138/172 | 0.47 | 0.11, 1.95 |
| Slattery 2007 (74) | 25–79 | PCC | BMI age 30 y | ≥30 vs. <25 | 311/312 | 0.46 | 0.25, 0.84 | 171/2292,3 | 1.19 | 0.56, 2.54 |
| John, 2011 and 2013 (45, 46) | 35–79 | PCC | BMI in 20s | High vs. low quantile4 | 370/458 | 0.65 | 0.41, 1.04 | 346/642 | 0.63 | 0.45, 0.90 |
| >23.7 vs. ≤21.2 ER+PR+ | — | — | — | 174/642 | 0.80 | 0.51, 1.25 | ||||
| John, 2015 (76, 77)5 | 25–79 | Pooled PCC6 | BMI in 20s | Quartile 4 vs. quartile 17 ER+PR+ | 280/726 | 0.59 | 0.38, 0.93 | 270/906 | 0.718 | 0.46, 1.099 |
| Tertile 3 vs. tertile 110 ER−PR− | 135/726 | 0.50 | 0.31, 0.81 | 146/1198 | 0.79 | 0.49, 1.289 | ||||
| White, 2012 (47) | 45–7511 | Cohort | BMI age 21 y | ≥30 vs. 20–29.9 | 465/18,378 | 0.70 | 0.33, 1.49 | |||
| Recent BMI | ||||||||||
| Mayberry, 1994 (72) | 20–54 | PCC | Adult BMI | ≥32.3 vs. <24.9 | 148/167 | 1.312 | 0.5, 3.2 | |||
| Wenten, 2002 (73) | 30–74 | PCC | Usual BMI | ≥30 vs. <22 | 114/145 | 1.64 | 0.52, 5.11 | 138/172 | 1.32 | 0.47, 3.72 |
| Slattery, 2007 (74) | 25–79 | PCC | Current BMI | ≥30 vs. <25 | 327/329 | 0.96 | 0.63, 1.46 | 177/2382,3 | 0.80 | 0.44, 1.45 |
| John, 2011 and 2013 (45, 46) | 35–79 | PCC | Current BMI | ≥30 vs. <25 | 375/483 | 0.52 | 0.35, 0.77 | 375/7048 | 0.77 | 0.53, 1.12 |
| ER+PR+ | — | — | — | 190/7048 | 1.23 | 0.75, 2.01 | ||||
| John, 2015 (76, 77)5 | 25–79 | Pooled PCC6 | Current BMI | ≥30 vs. <25 ER+PR+ | 285/763 | 0.63 | 0.44, 0.92 | 293/95713 | 0.91 | 0.55, 1.51 |
| ER−PR− | 142/763 | 0.71 | 0.45, 1.12 | 152/1260 | 0.60 | 0.32, 1.11 | ||||
| White, 2012 (47) | 45–7511 | Cohort | Baseline BMI | ≥30 vs. 20–29.9 | 465/18,378 | 1.27 | 0.99, 1.61 | |||
| Weight gain | ||||||||||
| Wenten, 2002 (73) | 30–74 | PCC | Weight gain since 18 y | >14 vs. <4 kg | 114/145 | 1.87 | 0.82, 4.24 | 138/172 | 2.46 | 0.98, 6.17 |
| Slattery, 2007 (74) | 25–79 | PCC | Weight gain since 15 y | >25 vs. ≤5 kg | 315/322 | 1.38 | 0.76, 2.52 | 163/2162,3 | 0.76 | 0.35, 1.65 |
| John, 2011 and 2013 (45, 46) | 35–79 | PCC | Weight gain (kg) since 20s | High vs. low14 | 308/458 | 0.35 | 0.21, 0.59 | 328/6238 | 0.91 | 0.50, 1.66 |
| ER+PR+15 | 175/458 | 0.30 | 0.17, 0.52 | 168/6238 | 1.43 | 0.70, 2.94 | ||||
| John, 2015 (76, 77)5 | 25–79 | Pooled PCC6 | Weight gain (kg) since 20s | Quartile 4 vs. quartile 116 ER+PR+ | 242/662 | 0.82 | 0.54, 1.24 | 251/84213 | 1.75 | 1.02, 3.02 |
| Tertile 3 vs. tertile 117 ER−PR− | 126/662 | 0.86 | 0.54, 1.35 | 135/1110 | 1.08 | 0.57, 2.02 | ||||
| WC, WHR, WHtR | ||||||||||
| Slattery, 2007 (74) | 25–79 | PCC | WC | >40 vs. <35 inches | 323/329 | 1.04 | 0.66, 1.62 | 264/37522,3 | 0.81 | 0.47, 1.39 |
| WHR | >0.9 vs. <0.8 | 1.25 | 0.72, 2.18 | 0.77 | 0.39, 1.50 | |||||
| John, 2011 and 2013 (45, 46) | 35–79 | PCC | WC (cm) | High vs. low quantile18 | 363/471 | 0.74 | 0.47, 1.17 | 355/6788 | 1.79 | 1.14, 2.819 |
| ER+PR+ | 172/471 | 0.64 | 0.39, 1.05 | 181/6788 | 2.03 | 1.11, 3.709 | ||||
| WHtR | High vs. low quantile19 | 363/471 | 0.74 | 0.47, 1.17 | 355/6788 | 1.55 | 0.96, 2.509 | |||
| ER+PR+ | 172/471 | 0.61 | 0.37, 1.02 | 181/6788 | 1.83 | 0.97, 3.479 | ||||
| John, 2015 (76, 77)5 | 25–79 | Pooled PCC6 | WC (cm) | Tertile 3 vs. tertile 120 | 71/560 | 2.2721 | 0.92, 5.619 | 122/883 | 1.2321 | 0.63, 2.419 |
| WHR | Tertile 3 vs. tertile 122 | 71/560 | 1.9621 | 0.95, 4.069 | 122/882 | 0.9321 | 0.57, 1.53 | |||
ER, estrogen receptor; PC, prospective cohort study; PCC, population-based case-control study; PR, progesterone receptor; ref, reference; WC, waist circumference; WHR, waist-to-hip ratio; WHtR, waist-to-height ratio; +, positive; −, negative.
Includes in situ breast cancers (82–83% were invasive).
No recent postmenopausal hormone therapy use.
Premenopausal women: quartile 4 vs. quartile 1, BMI >24.9 vs. ≤20.9; postmenopausal women: tertile 3 vs. tertile 1, BMI > 23.7 vs. ≤21.2.
Excludes in situ breast cancers.
Pooled data from the San Francisco Bay Area Breast Cancer Study (45, 46) and the 4-Corners Breast Cancer Study (74).
Premenopausal women: quartile 4 vs. quartile 1, BMI >25.3 vs. <20.9; postmenopausal women: quartile 4 vs. quartile 1: BMI >25.1 vs. <21.0.
Never/noncurrent users of postmenopausal hormone therapy.
Further adjusted for current BMI.
Premenopausal women: tertile 3 vs. tertile 1, BMI >24.3 vs. <21.5; postmenopausal women: tertile 3 vs. tertile 1, BMI >23.8 vs. <21.2.
At baseline.
Risk estimate for women ages 20–54 y.
Never/noncurrent/nonrecent users of postmenopausal hormone therapy.
Premenopausal women: weight gain >20 vs. <3.1 kg; postmenopausal women: weight gain ≥30 vs. <3 kg.
Premenopausal women: weight gain > 10 vs. <3.1 kg; postmenopausal women: weight gain ≥30 vs. <3 kg.
Premenopausal women: quartile 4 vs. quartile 1, weight gain >20.4 vs. < 7.5 kg; postmenopausal women: quartile 4 vs. quartile 1, weight gain >23.6 vs. <9.1 kg.
Premenopausal women: tertile 3 vs. tertile 1, weight gain >17.3 vs. < 9.1 kg; postmenopausal women: tertile 3 vs. tertile 1, weight gain >20.4 vs. <10.7 kg.
Premenopausal women: quartile 4 vs. quartile 1, WC >98 vs. ≤78.7 cm; postmenopausal women: tertile 3 vs. tertile 1, WC >96.4 vs. ≤85 cm.
Premenopausal women: quartile 4 vs. quartile 1, WHtR >0.61 vs. 0.50; postmenopausal women: tertile 3 vs. tertile 1, WHtR >0.61 vs. 0.54.
Premenopausal women: tertile 3 vs. tertile 1, WC >0.94 vs. <82.9 cm; postmenopausal women: tertile 3 vs. tertile 1, WC >96.6 vs. <86.4 cm.
Restricted to subjects measured <12 mo after diagnosis/selection into the study.
Premenopausal women: tertile 3 vs. tertile 1, WHR >0.85 vs. <0.80.